3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now

Core Viewpoint - Despite high valuations in the stock market, there are still attractive investment opportunities in the healthcare sector, particularly in AstraZeneca, CVS Health, and Pfizer, which are trading at low earnings multiples and offer potential for growth [1][2]. AstraZeneca - AstraZeneca's stock is currently priced around $90, with a target of reaching $80 billion in annual revenue by 2030 and aiming for a core operating margin in the mid-30s [4]. - The company generated $58.1 billion in sales and $9.4 billion in earnings over the past 12 months, showing significant growth potential [5]. - AstraZeneca's forward P/E multiple is just under 18, below the S&P 500 average of 22, and it offers a dividend yield of 1.74% [7]. CVS Health - CVS Health's stock price is currently just under $80, having increased over 70% this year, and it has shown improved financial performance [8][10]. - Revenue for the first nine months of 2025 rose approximately 8% to $296.4 billion, with adjusted earnings per share projected between $6.55 and $6.65 for the full year [9]. - The stock's forward P/E is 11, indicating it is undervalued, and it offers a dividend yield of 3.42%, significantly higher than the S&P 500 average [11]. Pfizer - Pfizer's stock trades around $25, experiencing a 5% decline this year due to reduced demand for COVID-19 products, with projected sales of $62 billion [12][13]. - The stock has a forward P/E of less than 9, suggesting it is undervalued, with a consensus price target indicating a potential upside of over 10% [13]. - Pfizer's recent acquisition of Metsera for developing next-gen obesity therapies indicates a strategic pivot towards new growth opportunities, and it offers the highest dividend yield on the list at 6.87% [15].